Related Experiment Video
Updated: Jun 23, 2026
09:01
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Published on: September 27, 2013
Therapeutic angiogenesis for coronary artery disease
Saul Benedict Freedman1, Jeffrey M Isner
1Department of Cardiology, Concord Repatriation General Hospital, University of Sydney, Hospital Road, Concord, New South Wales 2139, Australia.
Annals of Internal Medicine
|January 5, 2002
Summary
Therapeutic angiogenesis using growth factors like VEGF and FGF shows promise for improving blood flow in ischemic conditions. Further research is needed to optimize treatments for conditions like coronary artery disease.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Molecular Biology
Background:
- Animal models demonstrate that angiogenic growth factors enhance nutrient perfusion via neovascularization in ischemia.
- Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF) are well-studied cytokines with angiogenic activity.
Purpose of the Study:
- To evaluate the efficacy of therapeutic angiogenesis in patients with end-stage coronary artery disease.
- To identify optimal strategies for safe and effective therapeutic myocardial angiogenesis.
Main Methods:
- Clinical trials involving administration of recombinant angiogenic growth factors (VEGF, FGF).
- Gene transfer studies for therapeutic angiogenesis.
- Placebo-controlled trials assessing intracoronary and intravenous recombinant protein administration.
Main Results:
- Early clinical trials showed increased exercise time and reduced anginal symptoms, with improved perfusion and left ventricular function.
- Larger placebo-controlled trials of recombinant protein administration have not yet demonstrated significant clinical benefits over placebo.
- Ongoing placebo-controlled studies are investigating gene transfer for therapeutic angiogenesis.
Conclusions:
- Optimizing therapeutic angiogenesis requires further clinical studies to determine ideal dosage, formulation, administration routes, and growth factor combinations.
- Investigating the role of endothelial progenitor cells or stem cells as adjunctive therapy is crucial.
- Future research should focus on identifying patient-specific growth factors or cells to optimize therapeutic neovascularization.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...